Scott Bradfield, MD, MBA
CURRICULUM VITAE
Scott M. Bradfield, M.D., M.B.A.
PERSONAL DATA
Address: 67 Nantucket Island Court, Ponte Vedra, FL 32081
Place of Birth: Palm Beach Gardens, Florida
Marital Status: Married – Wife, Lissi Bradfield
Children: Son - Cameron Bradfield, born 2002
Daughter - Lillian Bradfield, born 2005
Son – Quinn Bradfield, born 2007
PRESENT POSITION
Associate Division Chief 2012 - Present
Interim Division Chief 2021 - 2023
Attending Physician 2003 - Present
Nemours Children's Health - Jacksonville / Wolfson Children’s Hospital
Department of Pediatric Hematology/Oncology
807 Children’s Way
Jacksonville, FL 32207
(904) 697-3793
Medical Director, C.H.A.T. Adolescent and Young Adult Oncology Program 2012-Present
Nemours Children’s Specialty Care
EDUCATION
Master of Business Administration, 2014
Concentration in Medical Management
University of Massachusetts-Amherst
Isenberg School of Management
Amherst, Massachusetts
Doctor of Medicine 1997
University of South Florida, College of Medicine
Tampa, Florida
Bachelor of Science 1993
Duke University
Durham, North Carolina
POSTDOCTORAL TRAINING
Fellowship, Pediatric Hematology/Oncology 2000 - 2003
Children’s Hospital and Regional Medical Center
Seattle, Washington
Pediatric Service 1997 – 2000
Massachusetts General Hospital
Boston, Massachusetts
BOARD CERTIFICATION(S)
American Board of Pediatrics Maintenance of Certification 2005 – ongoing
Subspecialty in Pediatric Hematology/Oncology
Diplomate of the American Board of Pediatrics 2000 – ongoing
LICENSURE AND CERTIFICATION
Institute for Healthcare Improvement: Basic Certificate
In Quality and Safety 2019
Florida Medical License, Board of Health #ME 88124 2003 – Present
Drug Enforcement Administration certificate 2003 – Present
License to Practice Medicine and Surgery #MD00038695 2000 – 2005
Department of Health, State of Washington
Certificate of Limited Registration 1997 – 2000
Board of Registration in Medicine, Massachusetts
HONORS/AWARDS
2023 Student Teaching Apple Award for top faculty recognized for 2023
Outstanding teaching by the medical students
Castle Connolly Regional Top Doctor Award 2014, 2021
Jacksonville Magazine, Top Docs 2017, 2019
Physician Leadership Development Program, Nemours 2017-2018
Phi Kappa Phi inductee, 2014
Collegiate Honor Society
University of Massachusetts, Amherst chapter
Beta Gamma Sigma inductee, 2014
International Honor Society for Business Programs
University of Massachusetts, Amherst chapter
Highest Patient Satisfaction Score for 2010 for all Nemours 2011
Children’s Clinic Physicians in Florida
Merit Award, American Society of Clinical Oncology 2003
2003 Annual Meeting
Doctor’s Doctor Award, The 4th year Medical Student the graduating 1997
class would most like to have as their own doctor
Director’s Award, H.Lee Moffitt Cancer Center 1997
The most promising 4th year medical student entering Academic Oncology
Pediatric Clerkship Award, Top 3rd year student in Pediatrics 1997
Award for Academic Excellence 1997
4th year student ranked in the top 20 in the graduating class
Alpha Omega Alpha Honor Medical Society, Junior year inductee 1996
ACADEMIC APPOINTMENTS
Assistant Professor in Pediatrics, Mayo Clinic College of 2007-Present
Medicine, Rochester, Minnesota
Courtesy Assistant Professor in Pediatrics, University of Florida College of
Medicine – Jacksonville, Jacksonville, Florida 2011-Present
Instructor in Pediatrics, Mayo Clinic College of Medicine, 2005 –2007
Rochester, Minnesota
Senior Fellow, Fred Hutchinson Cancer Research Center 2001 – 2003
Seattle, Washington
Fellow, University of Washington Medical Center 2000 – 2003
Clinical Fellow in Pediatrics, Harvard Medical School 1997 – 2000
Boston, Massachusetts
HOSPITAL STAFF PRIVILEGES
Associate Division Chief, Pediatric Hematology/Oncology 2012 - Present
Attending Physician, Pediatric Hematology/Oncology, 2003 - Present
Nemours Children’s Specialty Care, Jacksonville, FL
Pediatric Hematology/Oncology Section Chief 2010 - Present
Attending Physician, Pediatric Hematology/Oncology, 2003 - Present
Wolfson Children’s Hospital, Jacksonville, FL
Attending Physician, Pediatric Hematology/Oncology, 2003 - 2013
Shands - Jacksonville Medical Center, Jacksonville, FL
PROFESSIONAL MEMBERSHIPS AND SOCIETIES
American College of Physician Executives, Member 2008 – 2010
Nemours Center for Childhood Cancer Research, Member 2008 - Present
Children’s Oncology Group, Full Member 2003 - Present
American Society of Hematology, Associate Member 2003 – 2011, 2015
American Society of Pediatric Hematology/Oncology, Associate Member 2001 – Present
ADMINISTRATION AND COMMITTEE MEMBERSHIPS
Medical Board, Wolfson Children’s Hospital
- Secretary 2013 - 2016
- Chief-of-Staff Elect 2017 - 2018
- Chief-of-Staff 2019 – 2020
- Immediate Past Chief-of-Staff 2021 - 2022
Co-Chair, EPIC Oncology transition team, Wolfson Children’s Hospital 2021- 2022
Member, Nemours Children’s Specialty Care – Jacksonville, 2011 – 2017
Physician Satisfaction Committee
Core Member, WolfPAC, Wolfson Children’s Hospital, 2010 - 2012
EMR Physician Advisory Committee
Chair, Nemours Children’s Specialty Care – Jacksonville, 2014 – 2020
Fellowship Clinical Competency Committee
Member, Fellowship Clinical Competency Committee 2014 - Present
Member, Nemours Children’s Clinic KidsHealth / Getwell:)network Cancer
Advisory Committee 2008 - 2011
Member, Nemours Children’s Clinic Safety Committee 2006 - 2010
Chairman, Cancer Committee, Nemours Children’s Specialty Care - Jacksonville/ 2005 – Present
Wolfson Children’s Hospital
Member, Ethics Committee, Wolfson Children’s Hospital 2004-2009, 2011- Present
Chairman, Ethics Committee, Wolfson Children’s Hospital 2004 - 2009
Chairman, Nemours Children’s Specialty Care - Jacksonville/Wolfson Children’s 2010 - 2021
Hospital Steering Committee
Member, Nemours Children’s Specialty Care - Jacksonville/Wolfson Children’s 2003 - 2021
Hospital Steering Committee
Member, Pharmacy and Therapeutics Committee, Wolfson Children’s Hospital 2003 – Present
COMMUNITY INVOLVEMENT
Dreams Come True Board of Directors, Member 2008 - Present
American Cancer Society, Duval Unit, Operating Board, Member 2008 - 2013
Pediatric Bioethics Conference organizing committee 2008
PedsCare / Community Hospice Reflective Practice Task Force 2005
Jacksonville Community Caring for Children Coalition Member – General coalition, 2004 - 2005
Steering committee and Education sub-committee
______________________________________________________________________________________________
LABORATORY EXPERIENCE
Senior Fellow, Fred Hutchinson Cancer Research Center, Seattle, WA 2001 – 2003
Fellow in Jerald Radich’s Experimental Pathology lab studying minimal
residual disease in leukemia, concentrating on monitoring WT1 as leukemic
marker, searching for novel MRD markers and documenting graft vs. leukemia
effect in ALL patients post-transplant.
CLINICAL RESEARCH INVESTIGATIONS
1. Principal Investigator for Nemours Children’s Specialty Care- Jacksonville, 2013 - Present
Children’s Oncology Group cooperative group. NCI National Community
Oncology Research Program (NCORP) Award [5 UG1 CA189958-08
PI: Caywood, Emi]
2. Institutional Principal Investigator, NIH Subaward out of SickKids. 2021 – 2023
Symptom Screening Linked to Care Pathways for Children with Cancer:
a Cluster Randomized Trial. [R01CA251112-01; PJT-169165 PI Sung, Lillian]
3. Implementing Family Psychosocial Risk Screening for Pediatric Health Equity. 2023
[RSG-19-122-01-CPPB PI Kazak, Anne]
4. Lead Investigator [Florida sites] in Cancer Care Delivery Research (CCDR) 2014 – 2019
Delivery Research (CCDR) for the Nemours NCORP. NCI National Community
Oncology Research Program (NCORP) Award [1 UG1 CA189958-01 PI: Sandler, Eric]
5. National Study Chair, Study Principal Investigator, HLMCC0402/ACCL0731 2007-2014
“Glutamic Acid to Decrease Vincristine Toxicity in Children with Cancer”
6. Institutional Principal Investigator, ARIAD AP23573-07-110, “A Multi- 2008-2010
Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669)
Administered QDx5 Every Other Week in Pediatric Patients with Advanced
Solid Tumors”
7. Institutional Principal Investigator, Pfizer A1501088, “An Open-Label, 2008-2009
Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmaco-
Kinetics, Safety and Tolerability of Voriconazole in Immunocompromised
Children Aged 2 to <12 Years Who are at High Risk for Systemic Fungal
Infection”
8. Institutional Prinicipal Investigator, "A Phase I Study of Irinotecan and 2010-2016
Bevacizumab with Temozolomide in Children with Recurrent/Refractory
Central Nervous System Tumors."
9. Co-investigator, “Clinician-Parent-Patient Communication in Pediatrics: 2011-2013
Cancer substudy, “ a Nemours Foundation internally-funded study.
______________________________________________________________________________________________
RESEARCH FUNDING
1. Title: Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial (SPARK).
Major Goals: Among children with newly diagnosed cancer, to determine if symptom screening and feedback to healthcare providers at least three times weekly and locally-adapted symptom management care pathways, when compared to usual care.
Project Number: R01CA251112-01 Name of PD/PI: Scott Bradfield, MD
Source of Support: The Hospital for Sick Children and NIH
Project/Proposal Start and End Date: (MM/YYYY) (if available): 08/2020 – 04/2025
Total Award Amount (including Indirect Costs): Per case reimbursement ($1,300 per patient)
Person Months (Calendar/Academic/Summer) per budget period= 0.12 person-month/annually
2. Title: Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial (SPARK).
Major Goals: Among children with newly diagnosed cancer, to determine if symptom screening and feedback to healthcare providers at least three times weekly and locally-adapted symptom management care pathways, when compared to usual care.
Project Number: PJT-169165 Name of PD/PI: Scott Bradfield, MD
Source of Support: The Hospital for Sick Children and the Canadian Institutes of Health Research (CIHR)
Project/Proposal Start and End Date: (MM/YYYY) (if available): 04/2020 – 03/2025
Total Award Amount (including Indirect Costs): Per case reimbursement ($750 per patient)
Person Months (Calendar/Academic/Summer) per budget period= 0.12 person-month/annually
3. Title: Implementing Family Psychosocial Risk Screening for Pediatric Health Equity
Major Goals: The goal of this study is to create and broadly disseminate an implementation toolkit to facilitate acceptable, feasible, and sustainable family psychosocial risk screening in English and Spanish. The PAT will be implemented across a national sample of 18 pediatric cancer programs in a comparative effectiveness study.
Project Number: RSG-19-122-01-CPPB Name of PD/PI: Kazak, A.E.
Source of Support: American Cancer Society
Project/Proposal Start and End Date: (MM/YYYY) (if available): 1/1/2020 – 12/31/2024
Total Award Amount (including Indirect Costs): $37,558
Person Months (Calendar/Academic/Summer) per budget period=0.84 person-month/annually
4. Title: Randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Major Goals: Fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax clinical trial
Project Number: ITCC-101/APAL2020D Name of PD/PI: Scott Bradfield, MD
Source of Support: LLS Pedal Initiative, LLC
Project/Proposal Start and End Date: (MM/YYYY) (if available): 11/2022 -
Total Award Amount (including Indirect Costs): Per case reimbursement (Arm A $135,783 per patient, Arm B $150,200 per patient)
Person Months (Calendar/Academic/Summer) per budget period=0.12 person-month/annually
IN-KIND
5. Summary of In-Kind Contribution: Nemours NCI Community Oncology Research Program (NCORP) and Cancer Care Delivery Research PI
Project/Proposal Start and End Date (MM/YYYY) (if available): 08/2019 – 07/2025
Person Months (Calendar/Academic/Summer) per budget period =1.2 person-months/annually
Estimated Dollar Value of In-Kind Information: $141,270
PRESENTATIONS/POSTERS AT NATIONAL MEETINGS
1. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy following
myeloablative stem cell transplant is an effective mode of local control in high-risk neuroblastoma. General Poster Session, ASCO 39th Annual Meeting, May 31, 2003. Poster: Scott Bradfield.
2. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G. Phase II study of
21-day continuous intravenous infusion (CIVI) topotecan for recurrent pediatric solid tumors: a Children’s Oncology Group Study (COG A09713). Poster Discussion Session, ASCO, 41st Annual Meeting, May 16, 2005. Poster: Scott Bradfield.
3. Agarwal V, Logie N, Morris C, Bradley J, Rotondo R, Bradfield S, Indelicato DJ. Esophagitis in the Multimodality Treatment of Thoracic Ewing Sarcoma: Incidence, Risk Factors, and Management. Poster session, American Society of Pediatric Hematology/Oncology Annual Meeting – ASPHO, Montreal, Canada, April 26-29, 2017.
4. McManus K, Zorrilla J, Scimeme J, Bradfield S. A Hidden Osteomyelitis Leading to Deep Venous Thrombosis and Pulmonary Embolism Confounded by Recent Trauma. Poster, Southern Society for Pediatric Research, New Orleans, LA, February 21-23, 2019.
5. Indelicato DJ, Rotondo RL, Mailhot R, Uezono H, Bradfield S, Agarwal V, Hol ML, Bradley JA “Treatment Outcomes Following 45 GyRBE in Children with Group III Orbital Embryonal Rhabdomyosarcoma.”. American Society for Radiation Oncology (ASTRO), Annual Meeting, Chicago, IL, September 15-19, 2019.
6. Indelicato DJ, Rotondo RL, Mailhot R, Uezono H, Bradfield S, Agarwal V, Hol ML, Bradley JA. “Treatment Outcomes Following 45 GyRBE in Children with Group III Orbital Embryonal Rhabdomyosarcoma.” Pediatric Radiation Oncology Society (PROS) Annual Meeting, Bangkok, Thailand, June 19-22, 2019.
7. Kharod SM, Indelicato DJ, Rotondo RL, Mailhot RV, *Uezono H, Morris C, Bradfield S, Sandler E, Bradley JA. Outcomes Following Proton Therapy for Ewing Sarcoma of the Cranium and Skull Base. American Society for Radiation Oncology (ASTRO), Annual Meeting, Digital Poster Question and Answer Session. Chicago, IL, September 15-19, 2019.
8. Indelicato DJ, Mailhot Vega RB, Viviers E, Morris C, Bradfield S, Aldana PR, Bradley JA. Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: an Update of the University of Florida Experience. 53rd Congress of the International Society of Paediatric Oncology (SIOP), Virtual, October 24, 2021.
9. Johnson MC, Bradley JA, Mailhot Vega R, Bradfield S, Morris C, Indelicato. Outcomes in Pediatric NRSTS Treated with Proton Radiotherapy. 54th Congress of the International Society of Paediatric Oncology (SIOP), Oral Presentation, Barcelona, Spain, September 29, 2022.
10. Giap F, Indelicato DJ, Mailhot Vega R, Morris C, Bradfield SM, Bradley JA. Local control for large unresectable intermediate risk pediatric rhabdomyosarcomas. American Society for Radiation Oncology (ASTRO), Annual Meeting, Quick Pitch presentation, San Antonio, TX, October 24, 2022.
11. Fortune EC, Indelicato DJ, Mailhot Vega RB, Bradfield SM, Bradley JA. Outcomes following Proton Radiotherapy for Pediatric Salivary Gland Tumors. American Society for Radiation Oncology (ASTRO), Annual Meeting, Poster Presentation, San Antonio, TX, October 23-26, 2022.
BIBLIOGRAPHY (Peer-reviewed articles)
1. Wright JA, Bradfield SM, Park JR, Hawkins DS. Prolonged survival after invasive aspergillosis: a single
institution review of eleven cases. J Pediatr Hematol Oncol 2003; 25: 286-291. PMID: 12679641
2. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy after
myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer
2004; 100: 1268-1275. PMID: 15022296.
3. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G.
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children’s
Oncology Group Study. Pediatr Blood Cancer 2006; 47(6): 790-794. PMID: 16435380.
4. Swota AH, Bradfield SM. “STOP” –ping Harm: When is State Intervention Justified? Pediatr Blood Cancer
2010; 54(1): 8-10. PMID: 19902558.
5. Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, Arrieta A, Graham ML, Bradfield SM, Baruch A,
Liu P. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770-9. PMID: 21968355.
6. Bradfield SM, Sandler E, Geller T, Tamura RN, Krischer JP. Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer. Pediatr Blood Cancer 2015;62:1004–1010. PMID: 25545757.
7. Swota AH, Bradfield S. Eliciting parental values and preferences in the medical decision-making process. Am J Bioeth. 2015;15(5):34-5. doi: 10.1080/15265161.2015.1021978. PMID: 25970390.
8. Bechtel A, Cheek B, Bradfield S. False lung metastasis: Concurrent Ewing sarcoma and bronchoalveolar carcinoma. J Pediatr Hematol Oncol 2018; 40:325-7. PMID: 29016412.
9. Agarwal V, Logie N, Morris CG, Bradley JA, Rotondo RL, Bradfield SM, Indelicato D, Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax. Pediatr Blood Cancer 2018; 65, e27006. doi: 10.1002/ pbc.27006. PMID: 29431250.
10. Rutland MO, Egelund TA, Ng JS, Bradfield SM, Egelund EF. Intravenous and oral posaconazole pharmacokinetics in a five-year-old with mucor: A case report and review of the literature. J Pediatr Pharmacol Ther 2019;24:528-533. doi:10.5863/1551-6776-24.6.528. PMID: 31719815.
11. Indelicato DJ, Rotondo RL, Mailhot Vega RB, Uezono H, Bradfield S, Agarwal V, Hol ML, Bradley JA. 45 GyRBE for
Group III Orbital Embryonal Rhabdomyosarcoma. Acta Oncol, 2019; 58(10):1404-9. doi:.10.1080/0284186X.2019.1627412. PMID: 31530120.
12. Kharod SM, Indelicato DJ, Rotondo RL, Mailhot Vega RB, Uezono H, Morris CG, Bradfield S, et al. Outcomes Following
Proton Therapy for Ewing Sarcoma of the Cranium and Skull Base. Pediatr Blood Cancer 2020 Feb;67(2):e28080. doi:10.1002/pbc.28080. PMID: 31736243.
13. Indelicato DJ, Rotondo RL, Krasin MJ, Mailhot Vega RB, Uezono H, Bradfield S, et al. Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2020 Apr 1;106(5):968-976.doi: 10.1016/j.ijrobp.2019.12.036. PMID: 31987977.
14. Schultz KAP, Nelson A, Harris AK, Finch M, Field A, Jarzembowski JA, Wilhelm M, …Bradfield S, et al. Pleuropulmonary blastoma-like peritoneal sarcoma; a newly described malignancy associated with biallelic DICER1 pathogenic variation. Mod Path 2020 Oct; 33:1922-9. doi: 10.1038/s41379-020-0558-4. PMID: 32415267.
15. Uezono H, Indelicato D, Rotondo RL, Mailhot Vega RB, Bradfield SM, Morris CG, Bradley JA .Treatment Outcomes after Proton Therapy for Ewing Sarcoma of the Pelvis. Int J Radiat Oncol Biol Phys 2020 Aug 1;107(5): 974-981. doi:10.1016/j.ijrobp.2020.04.043. PMID: 32437922.
16. Parekh AD, Indelicato DJ, Vega RBM, Rotondo RL, Morris CG, Bradfield S, Bradley JA. Proton radiotherapy for infant rhabdomyosarcoma: Rethinking young age as an adverse prognostic factor. Radiother Oncol 2021 May 21;163:215-220. doi:10.1016/j.radonc.2021.05.017. PMID: 34023329.
17. Johnston EE, Martinez I, Davis ES, Caudill C, et al.… on behalf of the POCC Consortium. [Bradfield SM, Member of POCC Consortium]. SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities. J Clin Onc 2021 Dec 1;39:3778-88. doi:10.1200/JCO.21.00702. PMID: 34694886.
18. Indelicato DJ, Vega RBM, Viviers E, Morris CG, Bradfield SM, Ranalli NJ, Bradley JA. Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: An Update of the University of Florida Experience. Int J Radiat Oncol Biol Phys 2022 Jan13:S0360-3016(22)00017-7. doi: 10.1016/j.ijrobp.2022.01.007. PMID: 35033584.
19. Indelicato DJ, Mailhot Vega RB, Viviers E, Morris CG, Bradfield SM, Gibbs, Bradley JA. Modern Therapy for Chest Wall Ewing Sarcoma: An Update of the University of Florida Experience. Int J Radiat Oncol Biol Phys 2022 Feb 14:S0360-3016(22)00157-2. doi:10.1016/j.ijrobp.2022.02.011. PMID 35176415.
20. Metts J, Harrington B, Salman E, Bradfield SM, Flanary J, Mosha M, Amankwah E, Stapleton S. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors. Childs Nerv Syst 2022 May;38(5):919-928. doi:10.1007/s00381-022-05479-7. PMID 35260913.
21. Shaw PH, Metts J, Amankwah E, Eslin DE, Bradfield S, Slayton WB, et al. Trends in Pediatric Cancer Care in Florida From 1981-2020: Changing Patterns in a Growing and Increasingly Diverse Population. Cureus. 2023 Feb 16:15(2): e35061. Doi:10.7759/cureus.35061. PMID 36938203.
22. Chalfant V, Riveros C, Bradfield SM, Stec AA. Impact of social disparities on 10 year survival rates in paediatric cancers: a cohort study. Lancet Reg Health Amer 2023 Apr; 20:100454. doi:10.1016/j.lana.2023.100454. PMID 36875264.
23. Vettese E, Sherani F, King AA, Yu L, Aftandilian C, Baggott C, Agarwal V, Nagasubramanian R, Kelly KM, Freyer DR, Orgel E, Bradfield SM, Kyono W, Roth M, Klesges LM, Beauchemin M, Grimes A, Tomlinson G, Dupuis LL, Sung L. Symptom management care pathway adaptation process and specific adaptation decisions. BMC Cancer. 2023;23(1):350. doi: 10.1186/s12885-023-10835-0. PMID 37069510.
24. Martin SD, Davis ES, Chen D, et al…on behalf of the POCC Consortium. [Bradfield SM, Member of POCC Consortium]. Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19. JAMA Onc 2023 May 11; e230525. doi:10.1001/jamaoncol.2023.0525. PMID: 37166782.
25. Chalfant V, Riveros C, Bechtel, A, Bradfield, SM, Stec AA. Impact of social disparities on 5 year survival rates in pediatric hematological malignancies. Journal of Pediatric Hematology and Oncology, accepted for publication on Oct 6 2023.
BOOK CHAPTERS AND INVITED ARTICLES
- Bradfield SM, Neudorf S, Rubin E, Sandler ES. Prevention and Treatment of Infectious Disease. In: Kline RM. ed. Pediatric Hematopoietic Stem Cell Transplantation. 1st ed. New York: Informa Healthcare; 2006, 27-63.
- Bradfield SM. Adolescent and Young Adult Oncology: Addressing a Need. Northeast Florida Medicine. 2015;66(2):47-50.
ABSTRACTS AND LETTERS
1. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy is an
effective mode of local control in high-risk neuroblastoma (Abstract #3239). Proc Am Soc Clin Oncol, 2003; 22:806.
2. Bradfield SM, Loken MR, Radich JP. Letter to the Editor: Graft-versus-leukemia effect in acute
lymphoblastic leukemia: The importance of tumor burden and early detection. Leukemia 2004; 18: 1156-1158. PMID: 15042107.
3. Bradfield S, Hawkins DS, Whitlock J, Krailo M, Franklin J, Adamson PC, Children’s Oncology Group.
Phase II study of 21-day continuous intravenous infusion (CIVI) topotecan for recurrent pediatric solid
tumors: A Children’s Oncology Group Study (COG A09713) (Abstract #8523). J Clin Oncol 2005;23,
supp 16S: 805s.
4. Eunpu DL, Bradfield S, Martin LS. An unusual presentation of Turner syndrome, ALL and TP53 in a 9 year old female. American College of Medical Genetics, March 2010, Albuquerque, NM.
5. Stapleton S, Hamblin F, Steinbrueck S, Bradfield S, Tuite G, Carey C, Storrs B. Feasibility of combination
therapy with bevacizumab, irinotecan, and temozolomide in children with central nervous system tumors. (Abstract Control Number:2010-A-262-ISPNO), Accepted for 14th International Symposium on Pediatric Neuro-Oncology – ISPNO,
June 20 – 23, 2010, Vienna, Austria.
6. Swota AH, Bradfield SM. Letter to the Editor: When is State Intervention Justified? An Ethics Consult Gone Bad – Response. Pediatr Blood Cancer 2010;54(7): 1055. PMID: 20222018.
7. Agarwal V, Logie N, Morris C, Bradley J, Rotondo R, Bradfield S, Indelicato DJ. Esophagitis in the Multimodality Treatment of Thoracic Ewing Sarcoma: Incidence, Risk Factors, and Management. American Society of Pediatric Hematology/Oncology Annual Meeting – ASPHO, April 26-29, 2017, Montreal, Canada.
8. Indelicato DJ, Rotondo RL, Mailhot R, Uezono H, Bradfield S, Agarwal V, Morris C, Bradley JA. Beware of pseudoprogression in group III pelvic rhabdomyosarcoma patients undergoing proton therapy for bladder preservation. Particle Therapy Co-operative Group Annual Meeting, Manchester, United Kingdom, June 2019.
9. Indelicato DJ, Rotondo RL, Mailhot R, Uezono H, Bradfield S, Agarwal V, Morris C, Bradley JA. Outcomes following proton therapy for group III pelvic rhabdomyosarcoma. Particle Therapy Co-operative Group Annual Meeting. Manchester, United Kingdom, June 2019.
10. Parekh A, Indelicato D, Mailhot Vega R, Rotondo R, Morris C, Bradfield S, Bradley J. Proton radiotherapy for infant rhabdomyosarcoma: Rethinking young age as an adverse prognostic factor. American Society for Radiation Oncology, Annual Meeting, Miami Beach, October 25 – 28, 2020.
11. Indelicato DJ, Mailhot Vega RB, Viviers E, Morris C, Bradfield S, Aldana PR, Bradley JA. Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: an Update of the University of Florida Experience. 53rd Congress of the International Society of Paediatric Oncology (SIOP), Virtual, October 21-24, 2021.
12. Johnson MC, Bradley JA, Mailhot Vega R, Bradfield S, Morris C, Indelicato. Outcomes in Pediatric NRSTS Treated with Proton Radiotherapy. 54th Congress of the International Society of Paediatric Oncology (SIOP), Barcelona, Spain, September 29, 2022.
14. Fortune EC, Indelicato DJ, Mailhot Vega RB, Bradfield SM, Bradley JA. Outcomes following Proton Radiotherapy for Pediatric Salivary Gland Tumors. American Society for Radiation Oncology, Annual Meeting, San Antonio, TX, October 23-26, 2022.
INVITED TALKS
- “Graft vs. Host Disease,” Bone Marrow Transplant Conference, St. Luke’s Hospital, 11/11/05.
- “Sinusoidal Obstruction Syndrome,” Bone Marrow Transplant RN Conference, Mayo Clinic, Jacksonville, 3/11/11.
- Medical Director, 36th Annual Seminar “Advances in Pediatric Hematology/Oncology” by the Florida Association
of Pediatric Tumor Programs. 11/7/13-11/9/13.
- “Developing, nurturing, and growing a mature, healthy, adolescent and young adult…program,” 37th Annual Seminar “Advances in Pediatric Hematology/Oncology” by the Florida Association of Pediatric Tumor Programs. 10/25/2014.
- “Orthopedic Manifestations of Pediatric Leukemias/Lymphomas,” Nemours Children’s Specialty Care Orthopedic Grand Rounds, 3/4/15.
- “Vascular and Lymphatic Malformations in Children,” Baptist Hospital CME presentation, 4/20/21.
Financial relationships
-
Type of financial relationship:There are no financial relationships to disclose.Date added:02/09/2024Date updated:02/09/2024